MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning announced that it has been approved for listing on the Nasdaq Capital Market.

Trading of the company on the big board is expected to begin on April 27, with the company to be listed under the symbol “MNMD”. The company is expected to continue to be listed on the Neo Exchange in Canada as well, with its symbol remaining unchanged.

Commenting on the achievement, CEO JR Rahn stated, “We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value.”

Silver47 Exploration Inc. — sponsored Sponsored · Silver47 Exploration Inc.

MindMed last traded at $2.67 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Goliath Extends Golden Gate Lode 130 Metres With 13.45 g/t Gold Equivalent Over 4.85 Metres

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Related News

MindMed Launches Psychedelic-Based Pain Treatment Project

Mind Medicine Inc. (NEO: MMED), also known as MindMed, announced today that it has launched...

Wednesday, May 5, 2021, 09:44:00 AM

Psychedelics: The Eight Capital Primer

Eight Capital recently produced a primer on the psychedelic sector saying that the companies are...

Monday, June 14, 2021, 03:38:00 PM

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and...

Wednesday, September 16, 2020, 04:15:00 PM

MindMed Reveals Favorable Results From Phase 1 Trial Of Drug Candidate For Opioid Withdrawal Treatment

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the topline results...

Thursday, May 19, 2022, 09:29:00 AM

MindMed Acquires HealthMode For $41.6 Million

MindMed (NEO: MMED) this morning announced that it will be acquiring that of HealthMode in...

Thursday, February 18, 2021, 08:21:32 AM